Drug intelligence / Profile preview

auremolimab

Development stage: Preclinical
Lead developer: Incyte
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Auremolimab is an investigational monoclonal antibody that targets the interleukin-15 receptor beta subunit (IL-15Rβ, also known as IL-2/15Rβ or CD122) and is being developed for the treatment of vitiligo. The drug depletes and inhibits autoreactive resident memory T-cells which contribute to the pathogenesis of vitiligo. Initially developed by Villaris Therapeutics, the asset was acquired by Incyte. As of the latest updates, auremolimab had reached the IND (Investigational New Drug) application stage with preclinical or early clinical phase development for vitiligo.[1][3][6][7][10][11]

Other names: auremolimabVM6VM-6VM 6INCA034460INCA-034460INCA 034460

Targets

IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on auremolimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on auremolimab.

Explore the full profile